The World Health Organization states pharmaceuticals represented a US $300 billion-a-year market globally as of 2015. The global pharmaceutical market is expected to surpass the US $400 billion by 2018, with the ten largest pharmaceutical companies altogether commanding about a third of the market. Companies in the pharmaceutical industry are symbolized by their sizeable expenditure on Research and Development and marketing initiatives in a bid to collect more revenue. The development of biopharmaceuticals serves a breakthrough for the industry and personalized therapies carry extremely large promise in the near future. Although mature markets continue to account for over half of all global revenue of the pharmaceutical industry, both large and alcove pharmaceutical companies are now waking up to the profitable potential that lies in growth markets.
The healthcare industry deals with the storage, exchange and management of healthcare records between laboratories, insurance agencies, hospitals, patients, and government bodies. The healthcare industry has seen aggressive growth over the last few years. New advances in the information technology domain, connected with the changing demands of patients and healthcare institutions, are combining to shape the future of the global healthcare information technology industry. Many countries are already taking the initiative in implementing extensive Electronic Health Records (EHRs) and as this trend spreads to more countries, several new areas will continue to emerge in the healthcare industry.
Mylotargﾠis a drug-linkedﾠmonoclonal antibodyﾠ(anﾠantibody-drug conjugate) that was used to treatﾠacute myeloid leukemiaﾠfrom 2000 to 2010. LPI (LP Information)' newest research report, the ﾓMylotarg Industry Forecastﾔ looks at past sales and reviews total world Mylotarg sales in 202 [...]
READ MOREIdhifa is a drug used to treat relapsed or refractoryﾠacute myeloid leukemiaﾠin people with specific mutations of theﾠisocitrate dehydrogenase 2ﾠ(IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test LPI (LP Information)' newest research report, the ﾓIdhifa Industry Fore [...]
READ MOREEnasidenib is a drug used to treat relapsed or refractoryﾠacute myeloid leukemiaﾠin people with specific mutations of theﾠisocitrate dehydrogenase 2ﾠ(IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test LPI (LP Information)' newest research report, the ﾓEnasidenib Drugs [...]
READ MOREGemtuzumab ozogamicinﾠis a drug-linkedﾠmonoclonal antibodyﾠ(anﾠantibody-drug conjugate) that was used to treatﾠacute myeloid leukemiaﾠfrom 2000 to 2010. LPI (LP Information)' newest research report, the ﾓGemtuzumab Ozogamicin Industry Forecastﾔ looks at past sales and reviews total w [...]
READ MOREEnasidenib is a drug used to treat relapsed or refractoryﾠacute myeloid leukemiaﾠin people with specific mutations of theﾠisocitrate dehydrogenase 2ﾠ(IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test LPI (LP Information)' newest research report, the ﾓEnasidenib Indus [...]
READ MOREBesponsa is anﾠantibody-drug conjugateﾠused to treat relapsed or refractory B-cell precursorﾠacute lymphoblastic leukemiaﾠ(ALL). LPI (LP Information)' newest research report, the ﾓBesponsa Industry Forecastﾔ looks at past sales and reviews total world Besponsa sales in 2022, providing a [...]
READ MOREInotuzumab ozogamicin is anﾠantibody-drug conjugateﾠused to treat relapsed or refractory B-cell precursorﾠacute lymphoblastic leukemiaﾠ(ALL). LPI (LP Information)' newest research report, the ﾓInotuzumab Ozogamicin Industry Forecastﾔ looks at past sales and reviews total world Inotuzumab [...]
READ MOREAtrianceﾠis aﾠchemotherapyﾠdrug used inﾠT-cell acute lymphoblastic leukemia. LPI (LP Information)' newest research report, the ﾓAtriance Industry Forecastﾔ looks at past sales and reviews total world Atriance sales in 2022, providing a comprehensive analysis by region and market sector o [...]
READ MOREArranonﾠis aﾠchemotherapyﾠdrug used inﾠT-cell acute lymphoblastic leukemia. LPI (LP Information)' newest research report, the ﾓArranon Industry Forecastﾔ looks at past sales and reviews total world Arranon sales in 2022, providing a comprehensive analysis by region and market sector of p [...]
READ MORESwedish porphyria is a rareﾠautosomalﾠdominantﾠmetabolic disorderﾠaffecting the production ofﾠhemeﾠresulting from a deficiency of theﾠporphobilinogen deaminase. It is the most common of the acute porphyrias. LPI (LP Information)' newest research report, the ﾓSwedish Porphyria Drugs I [...]
READ MORE
Pvt. Ltd.
